• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

固体脂质纳米载体能有效地穿过黏液并进入肠细胞 - 但我的肽在哪里?

Solid lipid nanocarriers diffuse effectively through mucus and enter intestinal cells - but where is my peptide?

机构信息

Gattefossé SAS, 36 Chemin de Genas, 69804 Saint-Priest Cedex, France; Univ Lyon, Université Claude Bernard Lyon 1, CNRS, LAGEPP UMR 5007, 43 Boulevard du 11 Novembre 1918, F-69100 Villeurbanne, France.

Université Catholique de Louvain, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, 1200 Brussels, Belgium.

出版信息

Int J Pharm. 2020 Aug 30;586:119581. doi: 10.1016/j.ijpharm.2020.119581. Epub 2020 Jun 27.

DOI:10.1016/j.ijpharm.2020.119581
PMID:32603838
Abstract

Peptides are therapeutic molecules with high potential to treat a wide variety of diseases. They are large hydrophilic compounds for which absorption is limited by the intestinal epithelial border covered by mucus. This study aimed to evaluate the potential of Hydrophobic Ion Pairing combined with Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) to improve peptide transport across the intestinal border using Caco-2 cell monolayers (enterocyte-like model) and Caco-2/HT29-MTX co-cultured monolayers (mucin-secreting model). A Hydrophobic Ion Pair (HIP) was formed between Leuprolide (LEU), a model peptide, and sodium docusate. The marked increase in peptide lipophilicity enabled high encapsulation efficiencies in both NLC (84%) and SLN (85%). After co-incubation with the nanoparticles, confocal microscopy images of the cell monolayers demonstrated particles internalization and ability to cross mucus. Flow cytometry measurements confirmed that 82% of incubated SLN and 99% of NLC were internalized by Caco-2 cells. However, LEU transport across cell monolayers was not improved by the nanocarriers. Indeed, combination of particles platelet-shape and HIP low stability in the transport medium led to LEU burst release in this environment. Improvement of peptide lipidization should maintain encapsulation and enable benefit from nanocarriers enhanced intestinal transport.

摘要

肽是具有治疗多种疾病潜力的治疗分子。它们是亲水性大的化合物,其吸收受到由黏液覆盖的肠上皮边界的限制。本研究旨在评估疏水离子对与固体脂质纳米粒(SLN)和纳米结构化脂质载体(NLC)相结合的潜力,以利用 Caco-2 细胞单层(肠细胞样模型)和共培养的 Caco-2/HT29-MTX 单层(分泌黏液模型)改善肽穿过肠边界的转运。莱普瑞肽(LEU)是一种模型肽,与十二烷基硫酸钠形成了疏水离子对(HIP)。肽疏水性的显著增加使 NLC(84%)和 SLN(85%)的包封效率都很高。与纳米颗粒共孵育后,细胞单层的共聚焦显微镜图像显示出颗粒的内化和穿过黏液的能力。流式细胞术测量证实,82%的孵育 SLN 和 99%的 NLC 被 Caco-2 细胞内化。然而,纳米载体并没有改善 LEU 穿过细胞单层的转运。实际上,颗粒的血小板形状和 HIP 在运输介质中的低稳定性导致 LEU 在这种环境中爆发释放。肽的脂质化的改善应能保持包封并使纳米载体增强的肠转运受益。

相似文献

1
Solid lipid nanocarriers diffuse effectively through mucus and enter intestinal cells - but where is my peptide?固体脂质纳米载体能有效地穿过黏液并进入肠细胞 - 但我的肽在哪里?
Int J Pharm. 2020 Aug 30;586:119581. doi: 10.1016/j.ijpharm.2020.119581. Epub 2020 Jun 27.
2
In-vitro evaluation of solid lipid nanoparticles: Ability to encapsulate, release and ensure effective protection of peptides in the gastrointestinal tract.固体脂质纳米粒的体外评价:包封、释放肽类物质并确保其在胃肠道中有效保护的能力。
Int J Pharm. 2019 Jun 30;565:409-418. doi: 10.1016/j.ijpharm.2019.05.037. Epub 2019 May 14.
3
Improved transport and absorption through gastrointestinal tract by PEGylated solid lipid nanoparticles.通过聚乙二醇化固体脂质纳米粒改善胃肠道的转运和吸收。
Mol Pharm. 2013 May 6;10(5):1865-73. doi: 10.1021/mp300649z. Epub 2013 Apr 5.
4
Oral delivery of therapeutic peptides and proteins: Technology landscape of lipid-based nanocarriers.口服递呈治疗性肽和蛋白质:基于脂质的纳米载体技术全景。
Adv Drug Deliv Rev. 2022 Mar;182:114097. doi: 10.1016/j.addr.2021.114097. Epub 2022 Jan 7.
5
Lipid-based nanosuspensions for oral delivery of peptides, a critical review.脂质纳米混悬剂用于口服递肽:批判性综述。
Int J Pharm. 2018 Apr 25;541(1-2):117-135. doi: 10.1016/j.ijpharm.2018.02.038. Epub 2018 Feb 21.
6
Dextran-protamine coated nanostructured lipid carriers as mucus-penetrating nanoparticles for lipophilic drugs.葡聚糖-鱼精蛋白包被的纳米结构脂质载体作为用于亲脂性药物的黏液穿透纳米颗粒
Int J Pharm. 2014 Jul 1;468(1-2):105-11. doi: 10.1016/j.ijpharm.2014.04.027. Epub 2014 Apr 16.
7
Utilization of solid lipid nanoparticles for enhanced delivery of curcumin in cocultures of HT29-MTX and Caco-2 cells.利用固体脂质纳米粒增强姜黄素在 HT29-MTX 和 Caco-2 细胞共培养物中的传递。
Food Funct. 2013 Sep;4(9):1410-9. doi: 10.1039/c3fo60180c.
8
Hydrophobic H-bond pairing: A novel approach to improve membrane permeability.疏水氢键配对:提高膜透过性的新方法。
Int J Pharm. 2020 Jan 5;573:118863. doi: 10.1016/j.ijpharm.2019.118863. Epub 2019 Nov 22.
9
Evaluation of drug permeation under fed state conditions using mucus-covered Caco-2 cell epithelium.在进食状态条件下使用覆盖黏液的 Caco-2 细胞上皮评估药物渗透。
Eur J Pharm Sci. 2018 Jun 15;118:144-153. doi: 10.1016/j.ejps.2018.02.032. Epub 2018 Mar 7.
10
Virus-Mimicking Mesoporous Silica Nanoparticles with an Electrically Neutral and Hydrophilic Surface to Improve the Oral Absorption of Insulin by Breaking Through Dual Barriers of the Mucus Layer and the Intestinal Epithelium.具有电中性和亲水性表面的病毒模拟介孔硅纳米粒子,通过突破黏液层和肠上皮细胞的双重屏障来提高胰岛素的口服吸收。
ACS Appl Mater Interfaces. 2021 Apr 21;13(15):18077-18088. doi: 10.1021/acsami.1c00580. Epub 2021 Apr 8.

引用本文的文献

1
Barriers and Strategies for Oral Peptide and Protein Therapeutics Delivery: Update on Clinical Advances.口服肽和蛋白质疗法给药的障碍与策略:临床进展最新情况
Pharmaceutics. 2025 Mar 21;17(4):397. doi: 10.3390/pharmaceutics17040397.
2
Microneedle patch with pure drug tips for delivery of liraglutide: pharmacokinetics in rats and minipigs.用于利拉鲁肽递送的纯药物尖端微针贴片:大鼠和小型猪的药代动力学
Drug Deliv Transl Res. 2025 Jan;15(1):216-230. doi: 10.1007/s13346-024-01582-1. Epub 2024 Apr 15.
3
Encapsulation of bioactive peptides: a strategy to improve the stability, protect the nutraceutical bioactivity and support their food applications.
生物活性肽的包封:一种提高稳定性、保护营养保健品生物活性并支持其食品应用的策略。
RSC Adv. 2022 Feb 23;12(11):6449-6458. doi: 10.1039/d1ra08590e. eCollection 2022 Feb 22.